PPARGC1A and Cachexia: Prior studies using MCK-PGC1α transgenic animals show attenuation of protein degradation pathways, including studies showing that these alterations were sufficient to promote phenotypic improvements against cachexia (Sandri et al. 2006; Sacheck et al. 2007; Brault et al. 2010; Cannavino et al. 2014, 2015; Kang and Ji 2016; Wang et al. 2017).